DingYuan Fan

DingYuan Fan

Auto-generated profile, based on publicly available information

DingYuan Fan

Sydney Musculoskeletal Health, The Kolling Institute, the University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Arthroscopy
Verified
Journal Article
Closed access
DFDingYuan Fan
DingYuan Fan
XLXiaoHua Liu
XiaoHua Liu
JMJia Ma
Jia Ma
SZSheng Zhang
Sheng Zhang
JSJin Sun
Jin Sun
LZLei Zhang
Lei Zhang

1 November 2021 in JSES Reviews, Reports, and Techniques
Verified
Journal Article
Open access
DFDingYuan Fan
DingYuan Fan
JMJia Ma
Jia Ma
LZLei Zhang
Lei Zhang
Tranexamic acid (TXA) reduces blood loss in knee and hip arthroplasty, but the effectiveness in shoulder arthroplasty is unknown. This study aimed to evaluate current level I randomized controlled trials examining the efficacy of TXA in primary shoulder arthroplasty. A protocol for the study was designed and registered with PROSPERO (CRD42021230398). The PubMed, Embase, and Cochrane Library databases were searched using the following search strategy: “shoulder replacement” OR “shoulder arthroplasty” OR “reverse shoulder arthroplasty” AND “tranexamic acid.” All randomized controlled trials were included in this study. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was followed. Outcomes include blood loss, drain output, hemoglobin, thromboembolic complications, and blood transfusion. Five randomized controlled trials of 435 patients (219 patients in the TXA group and 216 patients in the non-TXA group) were included in the systematic review. The results indicated that the group using TXA had less total blood loss (MD, −249.56 mL; 95% confidence interval [CI] −347.60 to −151.52), less drainage output (MD, −113.72 mL; −155.92 to −71.52 95% CI), and less of a change in hemoglobin (MD, −0.68 g/dl; −0.94 to −0.42 g/dl 95% CI). No significant differences in blood transfusion (risk ratio 0.40; −0.11 to 1.45 95% CI) or thromboembolic events (risk ratio 0.13, 0.02 to 1.12 95% CI) were observed. Subgroup analyses showed that there was no significant difference in total blood loss, drainage output, or change in hemoglobin between single dose and multiple doses. TXA in primary shoulder arthroplasty can reduce blood loss, drain output, and hemoglobin changes. Subgroup analysis showed that multiple TXA doses have similar results compared with single dose in primary shoulder arthroplasty. More randomized controlled trials comparing different administration routes of TXA in primary and revision shoulder arthroplasty are required.

1 September 2023 in Journal of Orthopaedic Surgery
Verified
Journal Article
Open access
DFDingYuan Fan
DingYuan Fan
XLXiaoHua Liu
XiaoHua Liu
LZLei Zhang
Lei Zhang
Purpose: To determine whether a double anchor is more effective than a single anchor in the surgical repair of the anterior talofibular ligament (ATFL) in patients with ankle instability. Methods: This study searched PubMed, Embase and the Cochrane Library to identify potential studies that compared the clinical outcomes of double anchors and single anchors for ATFL repair from inception to July 31st, 2023. The study aligned with the 2020 Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines and checklist. The Risk of Bias in Nonrandomized Studies-of Interventions (ROBINS-I) tool was used to evaluate methodologic quality and risk of bias. The meta-analysis was performed with random effects. Outcomes, including American Orthopaedic Foot & Ankle Society Score (AOFAS), Karlsson Ankle Functional Score (KAFS), Tegner activity score, return to sport rate, complications and revision surgery events, were recorded. Results: A total of 845 articles were identified after an initial search of the three databases. Four retrospective studies involving 231 individuals were included for further analysis. There was no significant difference between the single-anchor group and the two-anchor group in terms of the AOFAS (risk ratio, −0.44, [−2.22; 1.34]) or KAFS (mean difference, −2.81, [−6.87; 1.25]). However, in terms of the Tegner activity score and the return to sport rate, the single-anchor group had significantly lower scores and longer times than the double-anchor group. No complications or revision surgery events were reported. Conclusions: In patients with chronic ankle instability, both single anchors and double anchors can provide good functional outcomes. For patients who participate in physically demanding sports, double anchors may be a superior option. Level of Evidence: Level Ⅲ, meta-analysis of Level Ⅲ


30 October 2026 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Open access
DFDingYuan Fan
DingYuan Fan
DHDavid Hunter
David Hunter
Platelet-rich plasma (PRP) and mesenchymal stromal cell (MSC) therapies are among the most widely used regenerative interventions for knee osteoarthritis (OA). Despite being driven by a broadly similar regenerative concept, important differences in biological characteristics, evidence availability, and regulatory requirements mean that they should not be regarded as broadly comparable therapies. At the same time, conflicting findings from clinical trials and evidence syntheses continue to shape interpretation and clinical decision-making. Substantial heterogeneity across products, treatment protocols, patient populations, and study designs has further complicated the evidence base. Yet as public enthusiasm and commercialization continue to accelerate, these uncertainties are often overshadowed by simplified narratives and therapeutic expectations. Amid this uncertainty, clinical interpretation should prioritise reliable evidence over expectation-driven narratives. In this rapidly evolving landscape, regenerative therapies should be considered through a cautious, evidence-based, and guideline-informed lens. Current evidence does not support routine, indiscriminate, or first-line use of regenerative injections in knee OA. PRP may be discussed as a selective option for carefully selected patients after inadequate response to established conservative treatments, but uncertainty about the magnitude and durability of benefit, together with caveats related to reporting limitations, spin, and costs, should be clearly communicated to support shared decision-making. MSC-based and other cell-based therapies remain less established and require further rigorous evaluation before broader clinical adoption.

1 October 2026 in Osteoarthritis Imaging
Verified
Journal Article
Open access
DHDavid Hunter
David Hunter
DFDingYuan Fan
DingYuan Fan